BASEL, Switzerland, February 4 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of Philippe Lutz MA Finance, as the company's first chief financial officer, effective immediately. He will be based at Synosia's new headquarters in Basel, Switzerland.

Lutz joins Synosia from Credit Suisse Investment Banking where he most recently served as a vice president of the global markets solutions group. In a nine-year career at Credit Suisse, he contributed to a broad range of capital market transactions and successfully completed the chartered financial analyst exams (CFA). Lutz is a Swiss national and earned his masters in business administration from the University of St. Gallen.

"Since Synosia started operations just over two years ago, we've established partnerships with Roche, Novartis and Syngenta, designed and completed our first clinical trial, prepared to start four phase II trials later this year, and built strong teams in both San Francisco and Basel," said the company's Chief Executive Officer and President Ian Massey.

"The establishment of our corporate headquarters in Switzerland and the appointment of Philippe Lutz is a further step in our progression to a mature development organization; it also underscores the importance of Switzerland as a centre of excellence for the management, clinical development and extension of our portfolio of compounds," Dr Massey continued.

"I knew that Synosia was the company I wanted to join once I met the management team and saw the extraordinary progress the company has made," said Lutz. "I was also pleased to learn of the new headquarters in Switzerland. The strength of Switzerland's pharmaceutical sector should help sustain Synosia's ambitious development programme."

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into new neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's corporate headquarters is in Basel, Switzerland.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact: Synosia Therapeutics In Europe: Julie Walters at Tudor Reilly Tel: +44(0)20-7016-7714 Mobile +44(0)775-3626967 julie.walters@tudor-reilly.com In US: Michele Parisi at Tudor Reilly Tel: +1-925-864-5028 michele.parisi@tudor-reilly.com

Synosia Therapeutics, In Europe: Julie Walters at Tudor Reilly, Tel: +44(0)20-7016-7714, Mobile +44(0)775-3626967, julie.walters@tudor-reilly.com; In US: Michele Parisi at Tudor Reilly, Tel: +1-925-864-5028, michele.parisi@tudor-reilly.com